Literature DB >> 11261330

Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement.

A Draube1, R Pfister, M Vockerodt, S Schuster, D Kube, V Diehl, H Tesch.   

Abstract

In multiple myeloma, the polymerase chain reaction (PCR) of the Ig heavy chain with allele-specific oligonucleotide (ASO) primers is a common and well-described method of identifying the tumor clone in peripheral blood (PB), bone marrow (BM) or leukapheresis products (LA). A factor which is crucial to the detection of clonal Ig rearrangements lies in the 'purity' of the tumor tissue used for the consensus PCR. We describe the application of a method to enrich CD138 positive myeloma cells derived from weakly infiltrated PB-, BM- and LA-samples. These are subjected to immunomagnetic enrichment with the MACS system, using an CD138 antibody directly conjugated to magnetic beads to obtain an enriched tumor cell population and the subsequent amplification of tumor specific IgH rearrangements. We investigated 29 samples (ten PB, ten BM, nine LA) with a median myeloma cell content of 0.5%. The approach led to a median enrichment factor of 118. Tumor-specific rearrangements could be amplified reproducibly from samples containing less than 0.1% myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11261330     DOI: 10.1007/s002770000245

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

1.  Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting.

Authors:  Jana Cumova; L Kovarova; A Potacova; I Buresova; F Kryukov; M Penka; J Michalek; R Hajek
Journal:  Int J Hematol       Date:  2010-08-07       Impact factor: 2.490

2.  Microfabricated magnetic sifter for high-throughput and high-gradient magnetic separation.

Authors:  Christopher M Earhart; Robert J Wilson; Robert L White; Nader Pourmand; Shan X Wang
Journal:  J Magn Magn Mater       Date:  2009-05       Impact factor: 2.993

3.  Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission.

Authors:  Déborah Martínez-Baños; Beatríz Sánchez-Hernández; Guadalupe Jiménez; Georgina Barrera-Lumbreras; Olga Barrales-Benítez
Journal:  Exp Ther Med       Date:  2017-03-28       Impact factor: 2.447

4.  Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma.

Authors:  Herbert García-Castillo; Evelia Leal-Ugarte; Pablo César Ortiz Lazareno; Esperanza Barrera-Chairez; Víctor Hugo Rosales-García; Patricio Barros-Núñez
Journal:  Med Oncol       Date:  2014-03-01       Impact factor: 3.064

5.  Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients.

Authors:  Mihaiela L Dragoș; Iuliu C Ivanov; Mihaela Mențel; Irina C Văcărean-Trandafir; Adriana Sireteanu; Amalia A Titianu; Angela S Dăscălescu; Alexandru B Stache; Daniela Jitaru; Dragoș L Gorgan
Journal:  Int J Mol Sci       Date:  2022-07-07       Impact factor: 6.208

6.  Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.

Authors:  Zhaoyuan Zhang; Weili Wang; Dan Ma; Jie Xiong; Xingyi Kuang; Siyu Zhang; Qin Fang; Jishi Wang
Journal:  Aging (Albany NY)       Date:  2020-04-16       Impact factor: 5.682

7.  Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma.

Authors:  Tianling Ding; Jie Hao
Journal:  Mol Med Rep       Date:  2021-09-03       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.